Literature DB >> 15064729

IL-6 is required for glioma development in a mouse model.

Jakob Weissenberger1, Sébastien Loeffler, Andreas Kappeler, Manfred Kopf, Anton Lukes, Tatiana A Afanasieva, Adriano Aguzzi, Joachim Weis.   

Abstract

The pleiotropic cytokine interleukin-6 (IL-6) contributes to malignant progression and apoptosis resistance of various cancer types. Although IL-6 is elevated in malignant gliomas, and glioma cells respond to IL-6, its functional role in gliomagenesis is unclear. We have investigated this role of IL-6 in a mouse model of spontaneous astrocytoma by crossbreeding glial fibrillary acidic protein (GFAP)-viral src oncogene transgenic mice with IL-6-deficient mice. We show here that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis. Moreover, we demonstrate phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of transcription (STAT)3, a prerequisite for IL-6 signalling, in 51 human gliomas WHO grade II-IV and all experimental mouse tumours investigated. Together with the observation that STAT3 activation increases with malignancy, these findings indicate an important role for IL-6 in the development and malignant progression of astrocytomas. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064729     DOI: 10.1038/sj.onc.1207455

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  79 in total

1.  STAT3 tyrosine phosphorylation influences survival in glioblastoma.

Authors:  Peter Birner; Kalina Toumangelova-Uzeir; Sevdalin Natchev; Marin Guentchev
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.

Authors:  R Bonavia; M M Inda; S Vandenberg; S-Y Cheng; M Nagane; P Hadwiger; P Tan; D W Y Sah; W K Cavenee; F B Furnari
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

3.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

4.  Identification of expression quantitative trait loci of RPTOR for susceptibility to glioma.

Authors:  Liming Huang; Wenshen Xu; Danfang Yan; Lian Dai; Xi Shi
Journal:  Tumour Biol       Date:  2015-09-11

5.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

6.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 7.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.

Authors:  Winnie W Pong; Samantha B Higer; Scott M Gianino; Ryan J Emnett; David H Gutmann
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

Review 9.  STAT3 regulation of glioblastoma pathogenesis.

Authors:  Núria de la Iglesia; Sidharth V Puram; Azad Bonni
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

Review 10.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.